Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Olsson

Showing results (561-570 of 632) with videos related to

Pageof 64
Sort By:
Atherosclerosis. Supplements|November 9, 2004
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994T R Pedersen, J Kjekshus, K Berg, et al.
European Journal of Preventive Cardiology|January 18, 2015
Treat-to-target versus dose-adapted statin treatment of cholesterol to reduce cardiovascular riskDirk Müller-Wieland, Gerd Assmann, Rafael Carmena, et al.
Dose-Response : a Publication of International Hormesis Society|June 24, 2021
Exposure to Low to Moderate Doses of Ionizing Radiation Induces A Reduction of Pro-Inflammatory Ly6chigh Monocytes and a U-Curved Response of T Cells in APOE -/- MiceN Rey, T Ebrahimian, C Gloaguen, et al.
European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology|April 1, 2011
LDL cholesterol goals and cardiovascular risk during statin treatment: the IDEAL studyAnders G Olsson, Christina Lindahl, Ingar Holme, et al.
Journal of the American College of Cardiology|June 6, 2009
Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trialAlexander E Fraley, Gregory G Schwartz, Anders G Olsson, et al.
Journal of the American College of Cardiology|May 16, 2006
Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programLars G Olsson, Karl Swedberg, Anique Ducharme, et al.
Epilepsy & Behavior : E&B|July 3, 2015
Epilepsy in patients with primary brain tumors: The impact on mood, cognition, and HRQOLZ Rahman, C H Wong, M Dexter, et al.
The American Journal of Cardiology|June 12, 2012
Effectiveness and safety of laropiprant on niacin-induced flushingDarbie L Maccubbin, Fabian Chen, Jennifer Weimer Anderson, et al.
Circulation|September 22, 2025
Post-Myocardial Infarction Psychological Distress: A Scientific Statement From the American Heart AssociationGlenn N Levine, Robert M Carney, Beth E Cohen, et al.
The American Journal of Cardiology|May 12, 2009
Comparative effect of atorvastatin (80 mg) versus simvastatin (20 to 40 mg) in preventing hospitalizations for heart failure in patients with previous myocardial infarctionTimo E Strandberg, Ingar Holme, Ole Faergeman, et al.
Pageof 64

Showing results (561-570 of 632) with videos related to

Sort By:
Pageof 64
Atherosclerosis. Supplements|November 9, 2004
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994T R Pedersen, J Kjekshus, K Berg, et al.
European Journal of Preventive Cardiology|January 18, 2015
Treat-to-target versus dose-adapted statin treatment of cholesterol to reduce cardiovascular riskDirk Müller-Wieland, Gerd Assmann, Rafael Carmena, et al.
Dose-Response : a Publication of International Hormesis Society|June 24, 2021
Exposure to Low to Moderate Doses of Ionizing Radiation Induces A Reduction of Pro-Inflammatory Ly6chigh Monocytes and a U-Curved Response of T Cells in APOE -/- MiceN Rey, T Ebrahimian, C Gloaguen, et al.
European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology|April 1, 2011
LDL cholesterol goals and cardiovascular risk during statin treatment: the IDEAL studyAnders G Olsson, Christina Lindahl, Ingar Holme, et al.
Journal of the American College of Cardiology|June 6, 2009
Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trialAlexander E Fraley, Gregory G Schwartz, Anders G Olsson, et al.
Journal of the American College of Cardiology|May 16, 2006
Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programLars G Olsson, Karl Swedberg, Anique Ducharme, et al.
Epilepsy & Behavior : E&B|July 3, 2015
Epilepsy in patients with primary brain tumors: The impact on mood, cognition, and HRQOLZ Rahman, C H Wong, M Dexter, et al.
The American Journal of Cardiology|June 12, 2012
Effectiveness and safety of laropiprant on niacin-induced flushingDarbie L Maccubbin, Fabian Chen, Jennifer Weimer Anderson, et al.
Circulation|September 22, 2025
Post-Myocardial Infarction Psychological Distress: A Scientific Statement From the American Heart AssociationGlenn N Levine, Robert M Carney, Beth E Cohen, et al.
The American Journal of Cardiology|May 12, 2009
Comparative effect of atorvastatin (80 mg) versus simvastatin (20 to 40 mg) in preventing hospitalizations for heart failure in patients with previous myocardial infarctionTimo E Strandberg, Ingar Holme, Ole Faergeman, et al.
Pageof 64